Tenaya Therapeutics functions as a clinical-stage biotechnology enterprise dedicated to discovering, developing, and delivering potentially curative therapies that target the underlying genetic and molecular root drivers of heart disease rather than merely managing outward clinical symptoms. The organization leverages three core technology platforms—comprising adeno-associated virus (AAV) gene therapies, cellular regeneration approaches, and precision-medicine small-molecule programs—to address severe conditions like cardiomyopathies and heart failure. By correcting or compensating for cellular defects and inherited mutations that disrupt normal cardiac muscle function, Tenaya aims to transform cardiovascular medicine through single-treatment genetic interventions.